Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of Disease 2000. Part 1: estimates of blood pressure levels. J Hypertens. 2006;24(3):413–22. https://doi.org/10.1097/01.hjh.0000199801.72563.6f.

Article  CAS  PubMed  Google Scholar 

Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with Essential Hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67–76. https://doi.org/10.1111/jch.13437.

Article  CAS  PubMed  Google Scholar 

Park JB, Kario K, Wang JG. Systolic Hypertension: an increasing clinical challenge in Asia. Hypertens Res. 2015;38(4):227–36. https://doi.org/10.1038/hr.2014.169.

Article  PubMed  Google Scholar 

Guideline for the. Pharmacological treatment of Hypertension in adults. Geneva: World Health Organization; 2021.

Google Scholar 

Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice. Guideline for primary care of Hypertension (2019). Chin J Gen Pract. 2019;18(4):301–13. https://doi.org/10.3760/cma.j.issn.1671-7368.2019.04.002.

Article  Google Scholar 

Zhang J, Zhang Y. China heart failure registry study—a multicenter, prospective investigation for preliminary analysis on etiology, clinical features and treatment in heart failure patients. Chin Circulation J. 2015;30(5):413–6. https://doi.org/10.3969/j.issn.1000-3614.2015.05.002.

Article  Google Scholar 

Katsi V, Skalis G, Pavlidis AN, Makris T, Nihoyannopoulos P, Tousoulis D, Kallikazaros I. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial Hypertension? Eur Heart J Cardiovasc Pharmacother. 2015;1(4):260–4. https://doi.org/10.1093/ehjcvp/pvv031.

Article  CAS  PubMed  Google Scholar 

Eadie AL, Brunt KR, Herder M. Exploring the food and drug administration’s review and approval of entresto (sacubitril/valsartan). Pharmacol Res Perspect. 2021;9(3):e00794. https://doi.org/10.1002/prp2.794.

Article  PubMed  PubMed Central  Google Scholar 

Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, Senni M. Real-world effectiveness and safety of sacubitril/valsartan in Heart Failure: a systematic review. Int J Cardiol. 2021;331:164–71. https://doi.org/10.1016/j.ijcard.2021.01.061.

Article  PubMed  Google Scholar 

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66. https://doi.org/10.1016/S0140-6736(09)61966-8.

Article  CAS  PubMed  Google Scholar 

Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with Hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705. https://doi.org/10.1161/HYPERTENSIONAHA.113.02002.

Article  CAS  PubMed  Google Scholar 

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004. https://doi.org/10.1097/HJH.0000000000002453.

Article  CAS  PubMed  Google Scholar 

Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE, Authors/Task Force Members. 2023 ESH guidelines for the management of arterial Hypertension the task force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023. https://doi.org/10.1097/HJH.0000000000003480.

Article  Google Scholar 

Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O’Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators. Echocardiographic features of patients with Heart Failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74(23):2858–73. https://doi.org/10.1016/j.jacc.2019.09.063.

Article  CAS  PubMed  Google Scholar 

Di Lenarda A, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, Bilato C, Passantino A, Carluccio E, Villani A, Degli Esposti L, d’Agostino C, Peruzzi E, Poli S, Iacoviello M. Sacubitril/Valsartan in Heart Failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT Study). J Clin Med. 2023;12(2): 699. https://doi.org/10.3390/jcm12020699.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Huang T, Shen W, Xu X, Yang P, Zhu D, Fang H, Wan H, Wu T, Wu Y, Wu Q. Efficacy and safety of sacubitril-valsartan in Heart Failure: a meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7(6):3841–50. https://doi.org/10.1002/ehf2.12974.

Article  PubMed  PubMed Central  Google Scholar 

Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and Meta-analysis of randomized controlled trials. J Clin Med. 2021;10(13): 2824. https://doi.org/10.3390/jcm10132824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kario K. The Sacubitril/Valsartan, a first-in-Class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in Hypertension, Heart Failure, and Beyond. Curr Cardiol Rep. 2018;20(1):5. https://doi.org/10.1007/s11886-018-0944-4.

Article  PubMed  Google Scholar 

Houchen E, Loefroth E, Schlienger R, Proudfoot C, Corda S, Saha S, Satwase SK, Studer R. Hospitalization rates in patients with Heart Failure and reduced ejection fraction initiating sacubitril/valsartan or angiotensin-converting enzyme Inhibitors/angiotensin receptor blockers: a retrospective cohort study. Cardiol Ther. 2022;11(1):113–27. https://doi.org/10.1007/s40119-021-00252-4.

Article  PubMed  PubMed Central  Google Scholar 

Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor Neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail. 2018;11(4): e004745. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004745.

Article  CAS  PubMed  Google Scholar 

Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD. Prospective comparison of ARNI with ACEI to Determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) investigators. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in Heart Failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228–34. https://doi.org/10.1002/ejhf.580.

Article  CAS  PubMed  Google Scholar 

General Practitioner Branch of Chinese Medical Doctor Association. Chinese expert consensus on clinical use of sacubitril/valsartan for cardiovascular diseases in primary care. Chin Gen Pract. 2021;24(23):2885–90.

Google Scholar 

Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World J Cardiol. 2012;4(5):135–47. https://doi.org/10.4330/wjc.v4.i5.135.

Article  PubMed  PubMed Central  Google Scholar 

To TL, Doan TN, Ho WC, Liao WC. Prevalence of frailty among community-dwelling older adults in asian countries: a systematic review and meta-analysis. Healthc (Basel). 2022;10(5): 895. https://doi.org/10.3390/healthcare10050895.

Article  Google Scholar 

Li X, Zuo C, Chen C, Tian D, Li J, Fan L, Li X, Lv Q. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: a prospective cohort study. Int J Cardiol. 2023;371:244–51. https://doi.org/10.1016/j.ijcard.2022.09.050.

Article  PubMed  Google Scholar 

Bahat G, İlhan B, Tufan A, Kılıç C, Karan MA, Petrovic M. Hypotension under antihypertensive treatment and Incident hospitalizations of nursing home residents. Drugs Aging. 2022;39(6):477–84. https://doi.org/10.1007/s40266-022-00951-0.

Article  CAS  PubMed  Google Scholar 

Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–69. https://doi.org/10.1093/eurheartj/eht386.

Article  PubMed  Google Scholar 

Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, Sarzani R. Renal effects of sacubitril/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287–97. https://doi.org/10.1007/s11739-019-02111-6.

Article  PubMed  PubMed Central  Google Scholar 

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in Heart Failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077.

Article  CAS  PubMed  Google Scholar 

Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2011;4(5):578–88. https://doi.org/10.1161/CIRCHEARTFAILURE.111.961573.

Article  CAS  PubMed  Google Scholar 

Savarese G, Musella F, D’Amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail. 2014;2(2):148–58. https://doi.org/10.1016/j.jchf.2013.11.007.

Article  PubMed